Matteo M. Naldini

🧬 MD, PhD Molecular Medicine | Medical Oncology Resident @SanRaffaeleMI

[Matteo M. Naldini @MatteoMNaldini]

Great and timely work led by an amazing @NotiniGiulia

[Giulia Notini @NotiniGiulia]

🧵 1/10

Do you know everything about Trop2? 🤔

In this pan-cancer multi-omic analysis, we explored TACSTD2 expression, regulation, and biological associations across normal tissues and tumor types.

🔗https://t.co/WhTZRfT62R

[Matteo M. Naldini @MatteoMNaldini]

@Fondaz_Telethon @SanRaffaeleMI @MyUniSR Link to the paper!
https://t.co/VW2aJpWT23

[Matteo M. Naldini @MatteoMNaldini]

4. An in-vitro surrogate for a long-term clinical outcome 🔮 Our in-vitro readout of gene marking in the HSC cluster associated with the vector copy number later measured in patients ~1 year after gene therapy!

[Matteo M. Naldini @MatteoMNaldini]

This, as always, was a huge team effort. Many many thanks to the #GentnerLab at #SR-TIGET, my amazing co-first authors, and our funders and institutions. @Fondaz_Telethon @SanRaffaeleMI
@MyUniSR

[Matteo M. Naldini @MatteoMNaldini]

3. My personal highlights: we caught stem cells self-renewing ex vivo.
Two independent clonal-tracking methods recovered the SAME clonal mark in different mice given aliquots of one culture.
👯‍♀️ What this means: 1 HSC split into 2 daughter cells that retained stemness!

[Matteo M. Naldini @MatteoMNaldini]

2. First we characterised the problem at single-cell resolution.
By scRNA-seq we can zoom in on molecularly defined HSC clusters, focusing on specifically the rare cells that truly matter!

[Matteo M. Naldini @MatteoMNaldini]

Really happy to share our new paper in Molecular Therapy!
❓Can we expand haematopoietic stem cells (HSCs) outside the body without breaking them?
Most protocols are built for cord blood. We asked if they work for mobilised peripheral blood, the source most used in the clinics 🧵

[Matteo M. Naldini @MatteoMNaldini]

I owe a huge thank you to @GiampaoloBianch and all the Milan OSR team for their constant guidance and inspiration.
Honoured to join @Cambridge_Uni as a @myESMO Research Fellow, carrying forward our shared passion for patient-centred science 🔬💙

[Giampaolo Bianchini @BianchiniGP]

Couldn’t be prouder of @MatteoMNaldini for receiving the ESMO Research Fellowship 2025! 🌟
You’ve worked incredibly hard and truly earned this.
Deep thanks to @myESMO for always believing in and supporting the next generation of physician-scientists.

[Roberto Ferrara @RobertoFerrara_]

Want to dive into patterns, biomarkers and strategies to overcome primary and acquired resistance to immunotherapy in lung cancer?
Check out our review just published on @NatRevClinOncol. A master piece from @MartinReck2 @barlesi and many other kols! https://t.co/CnJnR7gbEL

[Federico Rossari @f_rossari]

🚨 New publication alert! @casadei_gardini
We investigated how early bevacizumab dose/time modifications (eBEVmod) impact the efficacy of Atezolizumab + Bevacizumab in advanced hepatocellular carcinoma (aHCC) treatment in a real-world setting.
📄 Read: https://t.co/nvwT4laTWu
👇

[Roberto Ferrara @RobertoFerrara_]

🆕Time to tailor chemo-IO in resected NSCLC. Reconstructed individual pts data show NEOAD= PERIOP in pCR, MPR, non-MPR. PERIOP performs well in pure-MPR (1-10%RVT). pCR or no-MPR deserve descalation or escalation strategies. @AntonioNuccio01 @giusvisc @FabioSalomone22 @JNCI_Now

[Samuele Ferrari @ferrari_sam93]

🚨 What if a single DNA typo could inflame the body and outcompete healthy blood cells?

🧬 This happens in #VEXAS syndrome. In our paper out today in @NatureMedicine we show how.

📖 Here: https://t.co/tnLCb1bv3Y

👇 A story of inflammation, clonal warfare and #CRISPR editing 🧵

[Giampaolo Bianchini @BianchiniGP]

🔥Impressed by PATINA trial results?
👉 the longest mPFS ever in breast cancer (44 mths)

Unexpected? Not really
- Our study (👇👇) explain the biological rational
- Supportive clinical trials (NA-PHER2, PERTAIN)

❗️CLEOPATRA trial did not allow ET maintenance

@SABCSSanAntonio

[Matteo M. Naldini @MatteoMNaldini]

Quality > Quantity.

[Ash Paul @pash22]

Scientists need more time to think
https://t.co/pmA1A2bINt via @Nature

[Marco Mariani @mariani_m97]

Excited to share our latest publication on @JAMANetworkOpen : "Completion rate and positive results reporting among immunotherapy trials in breast cancer, 2004-2023.”
#BreastCancerResearch @OncoAlert @SanRaffaeleMI

👇Check out some key insights below

[Annals of Oncology @Annals_Oncology]

In Annals of Oncology, @BiagioRicciutMD & coll. review challenges & opportunities for TMB & immunotherapy:
🔹Technical limitations
🔹Spatial & temporal heterogeneity
🔹Co-occuring genomic and non-genomic factors
🔹Strategies to improve predictivity
https://t.co/uEpHspy84F
2/2

[Giulia Notini @NotiniGiulia]

1/4
📢Calling all T-Dxd prescribers!💉

Out now in @FrontOncology our real-world study on the impact of antiemetic prophylaxis in patients treated with T-DXd highlighted the efficacy of the three-drug regimen (with NK1RA)

https://t.co/Z5vDBmyrTz

@LLicata88 @BianchiniGP
🧵👇🏻👇🏻